{"id":"https://openalex.org/W3141692201","doi":null,"title":"The clinical efficacy of FOLFOX combined with bevacizumab/cetuximab in the first line treatment of advanced colorectal cancer with wild-type KRAS","display_name":"The clinical efficacy of FOLFOX combined with bevacizumab/cetuximab in the first line treatment of advanced colorectal cancer with wild-type KRAS","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W3141692201","mag":"3141692201"},"language":"en","primary_location":{"id":"mag:3141692201","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZZLL201411010.htm","pdf_url":null,"source":{"id":"https://openalex.org/S50982539","display_name":"Tumori","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310317717","host_organization_name":"Wichtig","host_organization_lineage":["https://openalex.org/P4310317717"],"host_organization_lineage_names":["Wichtig"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Tumori","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042706186","display_name":"Xia Xue-min","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802939634","display_name":"Chinese PLA General Hospital","ror":"https://ror.org/04gw3ra78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802939634"]},{"id":"https://openalex.org/I4210160531","display_name":"Chinese People's Liberation Army","ror":"https://ror.org/05tf9r976","country_code":"CN","type":"government","lineage":["https://openalex.org/I4210160531"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xia Xue-min","raw_affiliation_strings":["First Department of Medical Oncology,Chinese People's Liberation Army General Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Medical Oncology,Chinese People's Liberation Army General Hospital","institution_ids":["https://openalex.org/I2802939634","https://openalex.org/I4210160531"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5042706186"],"corresponding_institution_ids":["https://openalex.org/I2802939634","https://openalex.org/I4210160531"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.42934713,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-colorectal-cancer","display_name":"advanced colorectal cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/kras-wild-type","display_name":"KRAS wild-type","score":0.9559999704360962},{"id":"https://openalex.org/keywords/folfox","display_name":"FOLFOX","score":0.8849999904632568},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9549999833106995},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7639999985694885},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9110000133514404},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.8920000195503235},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.3330000042915344}],"concepts":[{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.9473979473114014},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9025043845176697},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8779374361038208},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.8179199695587158},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8006942868232727},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6464192271232605},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6267135739326477},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5789375901222229},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.5769016742706299},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.3926863670349121},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.37569573521614075},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3548685312271118},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3126097321510315}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3141692201","doi":null,"is_oa":false,"landing_page_url":"http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZZLL201411010.htm","pdf_url":null,"source":{"id":"https://openalex.org/S50982539","display_name":"Tumori","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310317717","host_organization_name":"Wichtig","host_organization_lineage":["https://openalex.org/P4310317717"],"host_organization_lineage_names":["Wichtig"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Tumori","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2712978371","https://openalex.org/W2921623917","https://openalex.org/W3095371297","https://openalex.org/W2005348280","https://openalex.org/W2939662662","https://openalex.org/W2130948044","https://openalex.org/W2898109351","https://openalex.org/W2891098128","https://openalex.org/W2986274861","https://openalex.org/W2891480174"],"abstract_inverted_index":{"Objective:To":[0],"compare":[1],"the":[2,17,32,84,89,93,182,192],"effi":[3,212],"cacy":[4],"and":[5,36,106,111,125,128,140,178,194,216],"main":[6],"side":[7,85],"effects":[8,86],"of":[9,43,78,144],"bevacizumab":[10,64,115],"vs":[11],"cetuximab":[12,71,130],"plus":[13],"FOLFOX":[14,61,67,74,98,118,133,145,157,188],"regimen":[15,99,119,134,146,158,189],"as":[16],"fi":[18],"rst-line":[19],"treatment":[20],"in":[21,52,114,129,153,176,197],"advanced":[22,198],"colorectal":[23,46,199],"cancer":[24,47,200],"patients":[25,39,90,201],"with":[26,48,66,73,117,132,156,187,202],"wild-type":[27,49,203],"KRAS":[28,50],"gene,and":[29],"to":[30],"evaluate":[31],"survival.Methods:Between":[33],"January":[34],"2008":[35],"February":[37],"2014,72":[38],"were":[40,87,91,109,123,138,171],"pathologically":[41],"diagnosed":[42],"stage":[44],"\u2163":[45],"gene":[51],"People's":[53],"Liberation":[54],"Army":[55],"General":[56],"Hospital.Of":[57],"72":[58],"patients,28":[59],"received":[60,63,70],"regimen,17":[62],"combined":[65,72,116,131,155,186,206],"regimen,and":[68],"27":[69],"regimen.After":[75],"three":[76,183],"cycles":[77],"chemotherapy,the":[79],"short-term":[80],"response":[81,102],"was":[82,96,148],"evaluated;":[83],"observed.All":[88],"followed-up,and":[92],"progression-free":[94],"survival(PFS)":[95],"calculated.Results:In":[97],"group,the":[100],"objective":[101],"rate(ORR),disease":[103],"control":[104],"rate(DCR)":[105],"median":[107,179,195],"PFS":[108,180,196],"14.3%,75.0%":[110],"8.0":[112],"months,respectively;":[113,127],"group,these":[120,135],"outcome":[121,136],"measurements":[122,137],"64.7%,94.1%":[124],"10.0":[126],"59.3%,92.6%":[139],"9.2":[141],"months,respectively.The":[142],"ORR":[143],"group":[147],"significantly":[149],"lower":[150],"than":[151],"those":[152],"bevacizumab/cetuximab":[154],"groups(\u03c72":[159],"=":[160,162,166,168],"12.101,P":[161],"0.000":[163,169],"5;":[164],"\u03c72":[165],"12.014,P":[167],"5).There":[170],"no":[172],"signifi":[173],"cant":[174],"differences":[175],"DCR":[177],"among":[181],"groups(P":[184],"0.05).Conclusion:Bevacizumab/cetuximab":[185],"can":[190],"improve":[191],"ORR,DCR":[193],"KRAS.These":[204],"two":[205],"regimens":[207],"have":[208],"a":[209],"quite":[210],"similar":[211],"cacy,less":[213],"adverse":[214],"reactions":[215],"good":[217],"tolerance.":[218]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2021-04-13T00:00:00"}